Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average) (2019 - 2026)

InMed Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $4.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 459.7% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 459.7%, while the annual FY2025 figure was $975985.0, 156.13% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $4.0 million at InMed Pharmaceuticals, roughly flat from $4.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $4.0 million in Q3 2025 and troughed at $700.0 in Q4 2023.
  • A 5-year average of $1.2 million and a median of $620127.0 in 2024 define the central range for Shares Outstanding (Weighted Average).
  • On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 100835.14% in 2024 and fell as far as 84.44% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $268793.0 in 2021, then skyrocketed by 98.32% to $533070.0 in 2022, then crashed by 99.87% to $700.0 in 2023, then surged by 100835.14% to $706546.0 in 2024, then surged by 459.7% to $4.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for INM at $4.0 million in Q4 2025, $4.0 million in Q3 2025, and $975985.0 in Q2 2025.